Thursday, July 29, 2021 2:32:02 PM
Yahoo Finance
July 29, 2021
https://finance.yahoo.com/news/nanalysis-scientific-corp-announces-8-120400545.html
CALGARY, AB, July 29, 2021 /CNW/ - (the "Company" or "Nanalysis"), (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Echelon Wealth Partners Inc. (the "Underwriters") pursuant to which the Underwriters have agreed to purchase 6,666,700 units (the "Units") from the treasury of the Company, at a price of $1.20 per Unit (the "Issue Price") and offer them to the public by way of a short form prospectus for total gross proceeds of approximately $8,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (each a "Common Share") and one-half of one common share purchase warrant (each full warrant, a "Warrant" and collectively the "Warrants"). Each whole Warrant shall entitle the holder thereof to acquire one Common Share for an exercise price of C$1.70 for period 24 months following the Closing Date.
The Company has granted the Underwriters an option to purchase up to an additional 15% of the Units at the Issue Price. The Over-Allotment Option may be exercised in whole or in part to purchase Common Shares, Warrants or Units as determined by the Underwriters upon written notice to the Company at any time up to 30 days following the Closing Date (the "Over-Allotment Option").
The Company intends to use the net proceeds of the Offering for sales, marketing, research and development, acquisitions, general administrative and working capital purposes.
The Offering will be completed (i) by way of a short form prospectus of the Company to be filed in British Columbia, Alberta, and Ontario, (ii) on a private placement basis in the United States pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company's securities under domestic or foreign securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Concurrently with the Offering the Company may conduct a non-brokered private placement for up to $5,000,000 of Units issued on the same terms as the Offering.
The Offering is expected to close on or about August 25, 2021, or such other date as the Company and the Underwriters may agree, and is subject to customary closing conditions, including the approval of the securities regulatory authorities and the TSX Venture Exchange.
About Nanalysis Scientific Corp. (TSXV: NSCI , OTCQX: NSCIF, FRA: 1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in with ticker symbol ' NSCI ' ,Over the Counter (OTC) in under the ticker symbol ' NSCIF ', and on the Frankfurt Exchange (FRA) under the symbol ' 1N1 '.
Nanalysis is an international business focused on capitalizing its proprietary technologies in magnetic resonance (MR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D S.A.S. (RS2D).
Nanalysis Corp. is an industry leader in developing and manufacturing compact MR spectrometers for laboratory and industrial markets. Its advanced 60 and 100 MHz spectrometers require no liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology.
Through its European subsidiary RS2D, the Company's electronic boards and software are used in conventional NMR and MRI equipment and are being incorporated into next-gen MRI systems as well as miniaturized MRI devices.
<<<
Recent NSCI News
- Nanalysis Announces Fourth Quarter and Full Year 2023 Results • PR Newswire (Canada) • 04/29/2024 08:05:00 PM
- /C O R R E C T I O N -- Nanalysis Scientific Corp./ • PR Newswire (Canada) • 04/24/2024 12:30:00 PM
- Nanalysis Announces Full Year 2023 Conference Call • PR Newswire (Canada) • 04/11/2024 12:30:00 PM
- Nanalysis Scientific Corp. Announces Director Resignation • PR Newswire (Canada) • 04/10/2024 01:55:00 PM
- AI Revolutionizes Drug Detection with Compact NMR and Machine Learning • AllPennyStocks.com • 04/04/2024 02:30:00 PM
- Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances • PR Newswire (Canada) • 04/04/2024 12:30:00 PM
- NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT • PR Newswire (Canada) • 03/20/2024 01:32:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NSCI • PR Newswire (Canada) • 03/06/2024 09:17:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - NSCI • PR Newswire (Canada) • 03/06/2024 09:15:00 PM
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NSCI • PR Newswire (Canada) • 03/06/2024 09:10:00 PM
- Canadian Investment Regulatory Organization Trading Halt - NSCI • PR Newswire (Canada) • 03/06/2024 09:07:00 PM
- NANALYSIS ANNOUNCES UP TO $5.0 MILLION BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND UP TO $1.0 MILLION CONCURRENT PRIVATE PLACEMENT • PR Newswire (Canada) • 03/06/2024 09:00:00 PM
- Nanalysis Announces Upcoming Webinar and Conference Participation • PR Newswire (Canada) • 02/07/2024 01:30:00 PM
- Nanalysis Achieves Record Revenue in Q4 • PR Newswire (Canada) • 02/06/2024 01:30:00 PM
- Nanalysis Scientific Corp. Provides Update on Security Services Business • PR Newswire (Canada) • 01/30/2024 01:30:00 PM
- Nanalysis Scientific Corp. Announces Grant of Restricted Share Units • PR Newswire (Canada) • 01/04/2024 12:11:00 AM
- Nanalysis Reports Third Quarter 2023 Results • PR Newswire (Canada) • 11/29/2023 10:19:00 PM
- Nanalysis Announces Third Quarter 2023 Conference Call • PR Newswire (Canada) • 11/15/2023 01:30:00 PM
- Nanalysis to Present at the Planet MicroCap Showcase: VANCOUVER 2023 on Wednesday, September 6, 2023 & 1x1 Meetings on Thursday, September 7, 2023 • PR Newswire (Canada) • 08/30/2023 12:30:00 PM
- Nanalysis Reports Second Quarter 2023 Results • PR Newswire (Canada) • 08/24/2023 08:05:00 PM
- Nanalysis Announces Second Quarter 2023 Conference Call • PR Newswire (Canada) • 08/15/2023 12:30:00 PM
- TSX Venture Exchange Stock Maintenance Bulletins • PR Newswire (Canada) • 06/30/2023 10:23:00 PM
- Nanalysis Enters into New Credit Facility with ATB Financial • PR Newswire (Canada) • 06/29/2023 11:40:00 PM
- Nanalysis To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar • PR Newswire (Canada) • 06/20/2023 08:05:00 PM
- Nanalysis Announces Annual General Meeting • PR Newswire (Canada) • 06/15/2023 01:07:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM